Inner Brightness Unveils New Akkermansia Probiotic: A Science-Backed Supplement for Gut Health and Digestion
SEATTLE, March 26, 2025 /PRNewswire/ -- Healthcare supplement brand Inner Brightness has introduced an innovation in the field of gut health with the launch of its new product, Akkermansia Probiotic, a next-generation gut health supplement designed to support gut health, digestion, and microbiome balance. This pioneering three-in-one formula uniquely combines pasteurized Akkermansia muciniphila AKK PROBIO, DigeSEB® broad-spectrum digestive enzymes, and B-Complex vitamins. The synergistic blend aims to enhance gut health, improve nutrient absorption, and support intestinal repair, marking a significant advancement in the science of probiotics.
The centerpiece of this formulation is Akkermansia muciniphila supplement, AKK PROBIO, one of the first heat-inactivated strains globally to receive GRAS (Generally Recognized as Safe) certification, ensuring compliance with the highest safety standards. This strain stands out not only for its safety and cleanliness but also for its immense potential in promoting gut wellness. Pasteurization enhances its stability while maintaining its ability to support key aspects of gastrointestinal health. It achieves this through Amuc1100 and Protein P9 on the surface of the inactivated bacteria, offering a safer, more hygienic, stable, and effective alternative to live bacteria. Research into Akkermansia muciniphila highlights its role in strengthening intestinal barrier health and optimizing gut microbiota composition, a critical factor for overall metabolic health.
To further boost digestive efficiency, Akkermansia Probiotic incorporates DigeSEB®, an advanced broad-spectrum enzyme blend known for digestion support across various food groups. By breaking down macronutrients such as proteins, carbohydrates, and fats more effectively, these enzymes help alleviate common issues like bloating while improving nutrient absorption.
The formula also features fortified B-Complex vitamins that contribute to energy metabolism and overall intestinal function. Essential B vitamins play an integral role not just in cellular energy production but also in maintaining nerve function and reducing inflammation associated with poor gut health.
Together, these three components create a powerful synergy that delivers benefits far beyond what each could achieve individually, a true case where one plus one plus one exceeds three. This innovative combination simultaneously restores the integrity of the intestinal lining (repair), improves nutrient breakdown (absorption), and supports metabolic processes (enhancement). It represents an all-encompassing approach that addresses multiple dimensions of gastrointestinal wellness at once.
The efficacy and quality of Akkermansia Probiotic as a leading microbiome support supplement, have earned recognition from health professionals who emphasize the critical role of gut health in overall well-being. Dr. Tina Krupczak, a board-certified dietitian-nutritionist with a Doctorate in Clinical Nutrition and a Master's in Nutrition and Integrative Health, highlights the importance of Akkermansia muciniphila and digestive support in fostering a balanced microbiome and optimal digestion.
"Gut health is the foundation of whole-body wellness. With Akkermansia Probiotic, we're combining some of the most researched ingredients to create a formula that supports digestion, nutrient absorption, and microbiome balance in a powerful way," said Dr. Tina Krupczak.
In terms of manufacturing standards, Inner Brightness ensures that every aspect meets rigorous quality controls by producing this product under GMP-certified facilities within the United States, aligning with FDA regulations, and undergoing third-party testing to validate both safety and effectiveness.
About Inner Brightness
Inner Brightness, a U.S.-based manufacturer, is dedicated to health and well-being through natural ingredients. Committed to quality, only the purest, most potent ingredients are selected, ensuring they are sustainably sourced and free from harmful additives. Production in state-of-the-art U.S. facilities guarantees the highest safety and quality standards. Innovation drives continuous research and development of new formulations, maximizing the benefits of natural ingredients. Transparency and honesty are core values, providing detailed information about every ingredient. Inner Brightness stands as a beacon of integrity, helping customers live healthier, more vibrant lives.
For more information, please visit:
Website: www.innerbrightness.com TikTok: https://www.tiktok.com/@innerbrightnessofficial Instagram: https://www.instagram.com/innerbrightnessofficial/
CONTACT: Inner Brightness Branding Team, official@innerbrightness.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/inner-brightness-unveils-new-akkermansia-probiotic-a-science-backed-supplement-for-gut-health-and-digestion-302411860.html
SOURCE Inner Brightness
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
42 minutes ago
- Yahoo
ERA Congress: Long-term data show sustained efficacy and safety of zigakibart in patients with IgA nephropathy
VIENNA, June 4, 2025 /PRNewswire/ -- New 100-week data from the ongoing Phase 1/2 study of zigakibart, an investigational anti-APRIL monoclonal antibody, reinforce its potential as a disease-modifying treatment for IgA nephropathy (IgAN). Findings presented today at the 62nd ERA Congress demonstrate sustained proteinuria remission, stable kidney function, and a reassuring safety profile. IgAN is the most common form of glomerular disease worldwide and a frequent cause of chronic kidney disease. Its pathogenesis is marked by inflammation and progressive kidney damage, which can lead to kidney failure. Many patients are unaware they have the condition until significant kidney damage has occurred, and 50% of IgAN patients will ultimately develop kidney failure. By targeting the APRIL pathway and reducing production of pathogenic galactose-debecause ofgA1), zigakibart addresses a key driver of disease progression. "Zigakibart is designed to intercept the initiating factor in IgAN pathogenesis, offering a new approach that may halt or significantly delay progression", explained lead investigator Professor Jonathan Barratt. The ADU-CL-19 trial included 40 adults with biopsy-confirmed IgAN and persistent proteinuria despite stable supportive therapy. Patients received zigakibart every two weeks via intravenous infusion or subcutaneous injection, in addition to maximally tolerated renin–angiotensin system inhibitors (RASi) unless RASi-intolerant – demonstrating efficacy beyond standard care. At Week 100, proteinuria was reduced by 60% from baseline. Over half of patients (55%) reached <500 mg/24 h, and 31% achieved <300 mg/24 h, indicating deeper remission. Estimated glomerular filtration rate (eGFR) remained stable across subgroups. "The consistency of eGFR stabilisation over 100 weeks, even across proteinuria response groups, is particularly encouraging," said Prof. Barratt. Treatment also led to sustained reductions in serum immunoglobulins, including a 74% drop in IgA and pathogenic Gd-IgA1, consistent with APRIL pathway inhibition. Zigakibart was well tolerated throughout. Most adverse events were mild or moderate, with no treatment-related serious infections or discontinuations. Infections were the most common AEs; the study coincided with a high prevalence of COVID-19. This is the longest duration of eGFR stabilisation reported for an anti-APRIL agent in IgAN. "These long-term results build confidence in zigakibart as a potential cornerstone therapy for IgAN," said Prof. Barratt. "We're excited to see how the upcoming Phase 3 trials will further define its role." The global Phase 3 BEYOND study is now evaluating zigakibart in a broader population, with primary proteinuria endpoints at 40 weeks and long-term kidney function through 104 weeks. View original content: SOURCE ERA Congress Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
LOS ANGELES, June 04, 2025--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on June 2, 2025, the Compensation Committee of Puma's Board of Directors approved the grant of inducement restricted stock unit awards covering 18,250 shares of Puma common stock to three new non-executive employees. The awards were granted under Puma's 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and provides for the granting of equity awards to new employees of Puma. The restricted stock unit awards vest over a three-year period, with one-third of the shares underlying the award vesting on the first anniversary of the award's vesting commencement date, June 1, 2025, and one-sixth of the shares underlying the award vesting on each six-month anniversary of the vesting commencement date thereafter, subject to continued service. The awards were granted as an inducement material to the new employees entering into employment with Puma, in accordance with Nasdaq Listing Rule 5635(c)(4). About Puma Biotechnology Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licensed the global development and commercialization rights to PB272 (neratinib, oral) in 2011. Neratinib, oral was approved by the U.S. Food and Drug Administration in 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX® (neratinib) tablets. In February 2020, NERLYNX was also approved by the FDA in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. NERLYNX was granted marketing authorization by the European Commission in 2018 for the extended adjuvant treatment of adult patients with early stage hormone receptor-positive HER2-overexpressed/amplified breast cancer and who are less than one year from completion of prior adjuvant trastuzumab-based therapy. NERLYNX® is a registered trademark of Puma Biotechnology, Inc. In September 2022, Puma entered into an exclusive license agreement for the development and commercialization of the anti-cancer drug alisertib, a selective, small molecule, orally administered inhibitor of aurora kinase A. Initially, Puma intends to focus the development of alisertib on the treatment of small cell lung cancer and breast cancer. In February 2024, Puma initiated ALISCA™-Lung1, a Phase II clinical trial of alisertib monotherapy for the treatment of patients with extensive-stage small cell lung cancer. In November 2024, Puma initiated ALISCA™-Breast1, a Phase II clinical trial of alisertib in combination with endocrine therapy for the treatment of patients with HER2-negative, HR-positive metastatic breast cancer. View source version on Contacts Alan H. Auerbach or Mariann Ohanesian, Puma Biotechnology, Inc., +1 424 248 6500info@ ir@
Yahoo
an hour ago
- Yahoo
Follicular Lymphoma Market Growth Accelerates at a CAGR of 6% During the Forecast Period (2025-2034) Due to the Advancements in Targeted Therapies
The follicular lymphoma market is expanding due to several factors. Increased awareness of the disease has led to a higher number of treated cases, contributing to market growth. Additionally, the rising number of clinical trials focused on the different treatment options for follicular lymphoma is a significant driver of its market's expansion. LAS VEGAS, June 4, 2025 /PRNewswire/ -- Follicular lymphoma is a typically slow-progressing B-cell lymphoproliferative disease that originates from transformed follicular center B cells. It is commonly marked by widespread lymph node enlargement, involvement of the bone marrow, and an enlarged spleen, while extranodal manifestations are relatively rare. As of 2024, approximately 35,000 cases of follicular lymphoma have been diagnosed across the 7MM, with both males and females having equal chances of getting the disease. First-line treatment for follicular lymphoma is well-established, with most patients experiencing durable responses to chemoimmunotherapy (CIT). For patients with localized disease, radiotherapy (RT) alone or in combination with immunochemotherapy is commonly used. RT alone may also be an option for localized relapses. Learn more about follicular lymphoma treatment guidelines @ Follicular Lymphoma Treatment Market The follicular lymphoma treatment landscape is broad and continuously evolving, offering multiple options for both newly diagnosed and relapsed/refractory (R/R) cases. Rituximab is the primary treatment option across the lines. It takes the highest market share as well as patient share. The availability of rituximab biosimilars has enhanced accessibility and affordability, maintaining its importance in managing the disease. Apart from rituximab, GAZYVA/GAZYVARO (obinutuzumab), which, when combined with chemotherapy, has become a key component in first-line treatment strategies. Its effectiveness in both treatment-naïve and relapsed patients has reinforced its central role in clinical practice. LUNSUMIO (mosunetuzumab) is a bispecific antibody therapy designed to treat adults with R/R follicular lymphoma who have already received two or more prior treatments. Approved in 2023, LUNSUMIO has already captured ~10% patient share in the third line of therapy. Furthermore, the future approvals in earlier lines can boost its market share. Multiple targeted therapies are making significant contributions. TAZVERIK (tazemetostat), an EZH2 inhibitor, provides a precision medicine approach for patients with specific genetic mutations. BRUKINSA (ibrutinib), a Bruton's tyrosine kinase inhibitor, although primarily approved for other B-cell cancers, also plays a role in follicular lymphoma treatment. Recent approvals have further expanded the arsenal, including EPKINLY/TEPKINLY (epcoritamab), a bispecific antibody targeting CD3 and CD20, as well as CAR T-cell therapies such as KYMRIAH (tisagenlecleucel), YESCARTA (axicabtagene ciloleucel), and BREYANZI (lisocabtagene maraleucel). These innovative immunotherapies are showing encouraging outcomes, particularly in the R/R setting, and are poised to reshape the therapeutic approach to follicular lymphoma by offering deeper and potentially long-lasting remissions. Find out more on FDA-approved follicular lymphoma treatment @ Follicular Lymphoma Drugs Market While ongoing research continues to explore new treatments, many approved therapies are already making a significant impact in the follicular lymphoma treatment landscape. The forecast period (2024–2034) is expected to bring further advancements, with emerging therapies enhancing existing treatment options. As healthcare spending continues to increase worldwide, the Follicular lymphoma treatment space is anticipated to see a positive shift, with more accessible and effective therapies becoming available to patients in need. Numerous drugs are currently in development for the treatment of follicular lymphoma, including promising therapies like Zilovertamab Vedotin (Merck Sharp and Dohme), CALQUENCE (acalabrutinib) (AstraZeneca), CTX112 (CRISPR Therapeutics), BGB-16673 (BeiGene), NKTR-255 (Nektar Therapeutics), NVG-111 (NovalGen), AS-1763 (docirbrutinib) (Carna Biosciences), Cemacabtagene Ansegedleucel (ALLO-501) (Allogene Therapeutics), Abexinostat (Xynomic Pharmaceuticals), Golcadomide (Bristol-Myers Squibb), MONJUVI (tafasitamab) (Incyte Corporation), AZD0486 (AstraZeneca), and others, which are set to launch in the 7MM during the forecast period (2024–2034). Discover which therapies are expected to grab major follicular lymphoma market share @ Follicular Lymphoma Therapy MONJUVI (tafasitamab) is a humanized monoclonal antibody that targets CD19 and has been engineered with an Fc domain to enhance cytolytic activity. It binds to CD19 proteins on B-cell surfaces, inhibiting their function and triggering cell death. The antibody works through apoptosis and immune-mediated mechanisms, including Antibody-dependent Cell-mediated Cytotoxicity (ADCC) and Antibody-dependent Cellular Phagocytosis (ADCP). In 2010, MorphoSys secured global exclusive rights to develop and commercialize tafasitamab from Xencor, Inc., which developed the Fc-engineered XmAb technology incorporated in the drug. In December 2024, Incyte presented pivotal findings from the Phase III inMIND trial at the ASH Annual Meeting. The study showed that combining MONJUVI with lenalidomide and rituximab significantly extended progression-free survival (PFS) in patients with relapsed or refractory (R/R) follicular lymphoma, achieving both the primary PFS endpoint and key secondary measures. AZD0486 (previously TNB-486) is an innovative CD19xCD3 bispecific T-cell engager (TCE) built on an IgG4 backbone. It features a low-affinity anti-CD3 domain designed to limit cytokine release while maintaining robust T-cell-driven cytotoxicity against malignant B cells. The molecule has a silenced Fc region to avoid nonspecific binding and ADCC, while ensuring prolonged half-life for intermittent dosing. AZD0486 is currently in Phase III development for follicular lymphoma. In November 2024, at ASH 2024, AstraZeneca emphasized its growing hematology pipeline through two oral presentations on AZD0486. Phase I trial data revealed strong efficacy in R/R follicular lymphoma patients, with an overall response rate (ORR) of 96% and a complete response rate (CRR) of 85% at doses of 2.4 mg and higher. Discover more about drugs for follicular lymphoma in development @ Follicular Lymphoma Clinical Trials The anticipated launch of these emerging therapies for follicular lymphoma are poised to transform the market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the follicular lymphoma market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth. DelveInsight estimates that the US market size for follicular lymphoma is expected to grow from USD 1 billion in 2024 at a significant CAGR by 2034. The follicular lymphoma market is experiencing steady growth, driven by rising incidence rates, increasing awareness, and advancements in targeted therapies such as monoclonal antibodies and CAR-T cell treatments. The aging global population further contributes to market expansion. Additionally, ongoing clinical trials and approvals of novel agents are expected to boost market opportunities in the coming years. DelveInsight's latest published market report, titled as Follicular Lymphoma Market Insight, Epidemiology, and Market Forecast – 2034, will help you to discover which market leader is going to capture the largest market share. The report provides comprehensive insights into the follicular lymphoma country-specific treatment guidelines, patient pool analysis, and epidemiology forecast to help understand the key opportunities and assess the market's underlying potential. The follicular lymphoma market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM, segmented into: Total Diagnosed Incidence Cases of Follicular Lymphoma Gender-specific Cases of Follicular Lymphoma Age-specific cases of Follicular Lymphoma Stage-Specific Cases of Follicular Lymphoma Grade-Specific Cases of Follicular Lymphoma Treated Case by Line of Therapy of Follicular Lymphoma The report provides an edge while developing business strategies by understanding trends shaping and driving the 7MM follicular lymphoma market. Highlights include: 10-year Forecast 7MM Analysis Epidemiology-based Market Forecasting Historical and Forecasted Market Analysis upto 2034 Emerging Drug Market Uptake Peak Sales Analysis Key Cross Competition Analysis Industry Expert's Opinion Access and Reimbursement Download this follicular lymphoma market report to assess the epidemiology forecasts, understand the patient journeys, know KOLs' opinions about the upcoming treatment paradigms, and determine the factors contributing to the shift in the follicular lymphoma market. Also, stay abreast of the mitigating factors to improve your market position in the follicular lymphoma therapeutic space. Related Reports Follicular Lymphoma Epidemiology Forecast Follicular Lymphoma Epidemiology Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted follicular lymphoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. Follicular Lymphoma Pipeline Follicular Lymphoma Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key follicular lymphoma companies, including Mab Works, AstraZeneca, ADC Therapeutics, Xynomic Pharmaceuticals, AbbVie, Nurix, InnoCare Pharma, LTZ Therapeutics, Hutchmed, Regeneron Pharmaceuticals, Pfizer, InnoCare Pharma, TriSalus Life Sciences, BeiGene, among others. Non-Hodgkin's Lymphoma Market Non-Hodgkin's Lymphoma Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key NHL companies, including AbbVie, Genmab, Novartis, Angiocrine Bioscience, Autolus, Zentera Therapeutics, Jiangsu Hengrui Medicine, among others. Non-Hodgkin's Lymphoma Pipeline Non-Hodgkin's Lymphoma Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key NHL companies, including Novartis, AstraZeneca, Genentech, BioInvent, Genmab, SystImmune, Nordic Nanovector, Pacylex Pharmaceuticals, Artiva Biotherapeutics, Inc., Chipscreen Biosciences, Ltd., Timmune Biotech Inc., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Gilead Sciences, Acerta Pharma BV, Adagene Inc, Conjupro Biotherapeutics, Inc., Rhizen Pharmaceuticals, Juventas Cell Therapy Ltd., Incyte Corporation, HUYA Bioscience International, SecuraBio, Genor Biopharma Co., Ltd., Kyowa Kirin Co., Ltd., Antengene Therapeutics Limited, Regeneron Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., Xynomic Pharmaceuticals, Inc., BioTheryX, Inc., UWELL Biopharma, Kronos Bio, Bio-Thera Solutions, Spectrum Pharmaceuticals, Inc., Aptose Biosciences Inc., Miltenyi Biomedicine GmbH, Precision BioSciences, Inc., Teneobio, Inc., TCR2 Therapeutics, IGM Biosciences, Inc., among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve. Contact UsShruti Thakur info@ +14699457679 Logo: View original content: SOURCE DelveInsight Business Research, LLP Sign in to access your portfolio
